Kimberly Shoenbill, MD, PhD
Kimberly Shoenbill, MD, PhD
Specialty: Internal Medicine
Program: Internal and Hospital Medicine
Language(s): English
-
Publications
- Jafarinia A, Shoenbill KA, Newcomer EH, Hartzell JA, Sealby BP, Finazzo GJ, Jones FM, Goldstein AO. Patient Satisfaction Survey for Inpatient Tobacco Cessation Treatment. Am J Health Promot. 2025 Sep. Pubmedid: 40934259.
- Shoenbill KA, Ostroff JS, Taylor KL, Jafarinia A, Minion M, Chichester LA, Omernik B, McCall M, Yeung S, Wiseman K, Chen LS, Salloum RG, Warren G. Recommendations for Standardization of Tobacco Use Treatment Data. J Thorac Oncol. 2025 Sep. Pubmedid: 41015336.
- Wong R, Matulewicz RS, Talwar R, Shoenbill KA, Goldstein AO, Bjurlin MA. Increased Tobacco Taxation Associated With Decreased Consumption and Bladder Cancer Incidence. Urol Pract. 2025 Mar.12(2):250-256. Pubmedid: 39454020.
- Wong R, Borgert B, Matulewicz RS, Goldstein AO, Shoenbill KA, Bjurlin MA. Analyzing Smoking Challenges in Bladder Cancer Patients From an Online Forum: A Contemporary Qualitative Study of Peer Support and Cessation Motivators. Tob Use Insights. 2025 Jun.18:1179173X251355758. Pubmedid: 40557331. Pmcid: PMC12185941.
- Trivedi H, Kay H, Reines K, Hartzell J, Newcomer E, Myers S, Matulewicz RS, Goldstein AO, Shoenbill KA, Bjurlin MA. Efficacy of Inpatient, Evidence-Based Tobacco Use Treatment of Patients With Bladder Cancer After Radical Cystectomy. Clin Genitourin Cancer. 2025 Feb.23(1):102252. Pubmedid: 39577125. Pmcid: PMC11757068.
- Salloum RG, Shoenbill KA, Goldstein AO. Economic Considerations for Implementing Tobacco Cessation Programs in Cancer Care Settings. Cancer Prev Res (Phila). 2024 May.17(5):197-199. Pubmedid: 38693901. Pmcid: PMC11110074.
- Chandi J, Soundararajan S, Bukowski W, Britt W, Weiss K, Matulewicz RS, Kay H, Goldstein AO, Shoenbill KA, Bjurlin MA. Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors. Bladder Cancer. 2024 Jun.10(1):61-69. Pubmedid: 38911483. Pmcid: PMC11192552.
- Kay H, Silver SN, Smith AB, Basak R, Shoenbill K, Usinger D, Goldstein AO, Matulewicz RS, Chen R, Bjurlin MA. Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health-Related Quality of Life Measures: An Assessment of the Comparative Effectiveness and Survivorship Health in Bladder Cancer (CEASE-BC) Study. J Urol. 2024 Jul.212(1):87-94. Pubmedid: 38603576. Pmcid: PMC11193885.
- Shoenbill KA, Goldstein AO. Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening. J Thorac Oncol. 2024 Apr.19(4):531-533. Pubmedid: 38582544.
- Pluta K, Hohl SD, D'Angelo H, Ostroff JS, Shelley D, Asvat Y, Chen LS, Cummings KM, Dahl N, Day AT, Fleisher L, Goldstein AO, Hayes R, Hitsman B, Buckles DH, King AC, Lam CY, Lenhoff K, Levinson AH, Minion M, Presant C, Prochaska JJ, Shoenbill K, Simmons V, Taylor K, Tindle H, Tong E, White JS, Wiseman KP, Warren GW, Baker TB, Rolland B, Fiore MC, Salloum RG. Data envelopment analysis to evaluate the efficiency of tobacco treatment programs in the NCI Moonshot Cancer Center Cessation Initiative. Implement Sci Commun. 2023 May.4(1):50. Pubmedid: 37170381. Pmcid: PMC10173908.
- Hohl SD, Matulewicz RS, Salloum RG, Ostroff JS, Baker TB, Schnoll R, Warren G, Bernstein SL, Minion M, Lenhoff K, Dahl N, Juon HS, Tsosie U, Fleisher L, D'Angelo H, Ramsey AT, Ashing KT, Rolland B, Nolan MB, Bird JE, Nguyen CVT, Pauk D, Adsit RT, Tindle HA, Shoenbill K, Yeung S, Presant CA, Wiseman KP, Wen KY, Chichester LA, Chen LS. Integrating Tobacco Treatment Into Oncology Care: Reach and Effectiveness of Evidence-Based Tobacco Treatment Across National Cancer Institute-Designated Cancer Centers. J Clin Oncol. 2023 May.41(15):2756-2766. Pubmedid: 36473135. Pmcid: PMC10331951.
- Weiss KG, Matulewicz RS, Moreton E, Shoenbill KA, Milowsky MI, Rose TL, Kim WY, Goldstein AO, Bjurlin MA. History of the Relationship Between Smoking and Bladder Cancer: A Public Health Perspective. Urology. 2023 Jan.171:6-10. Pubmedid: 35977631. Pmcid: PMC10225052.
- Hohl SD, Shoenbill KA, Taylor KL, Minion M, Bates-Pappas GE, Hayes RB, Nolan MB, Simmons VN, Steinberg MB, Park ER, Ashing K, Beneventi D, Cox LS, Goldstein AO, King A, Kotsen C, Presant CA, Sherman SE, Sheffer CE, Warren GW, Adsit RT, Bird JE, D'Angelo H, Fiore MC, Nguyen CVT, Pauk D, Rolland B, Rigotti NA. The Impact of the COVID-19 Pandemic on Tobacco Treatment Program Implementation at National Cancer Institute-Designated Cancer Centers. Nicotine Tob Res. 2023 Jan.25(2):345-349. Pubmedid: 35778237. Pmcid: PMC9384385.
- Fiore MC, Smith SS, Adsit RT, Bolt DM, Conner KL, Bernstein SL, Eng OD, Lazuk D, Gonzalez A, Jorenby DE, D'Angelo H, Kirsch JA, Williams B, Nolan MB, Hayes-Birchler T, Kent S, Kim H, Piasecki TM, Slutske WS, Lubanski S, Yu M, Suk Y, Cai Y, Kashyap N, Mathew JP, McMahan G, Rolland B, Tindle HA, Warren GW, An LC, Boyd AD, Brunzell DH, Carrillo V, Chen LS, Davis JM, Dilip D, Ellerbeck EF, Iturrate E, Jose T, Khanna N, King A, Klass E, Newman M, Shoenbill KA, Tong E, Tsoh JY, Wilson KM, Theobald WE, Baker TB. The first 20 months of the COVID-19 pandemic: Mortality, intubation and ICU rates among 104,590 patients hospitalized at 21 United States health systems. PLoS One. 2022 Sep.17(9):e0274571. Pubmedid: 36170336. Pmcid: PMC9518859.
- Feuer Z, Michael J, Morton E, Matulewicz RS, Sheeran P, Shoenbill K, Goldstein A, Sherman S, Bjurlin MA. Systematic review of smoking relapse rates among cancer survivors who quit at the time of cancer diagnosis. Cancer Epidemiol. 2022 Oct.80:102237. Pubmedid: 35988307. Pmcid: PMC10363369.
- Shoenbill KA, Newcomer E, Valcourt-Hall C, Baca-Atlas MH, Smith CA, Goldstein AO. An Analysis of Inpatient Tobacco Use Treatment Transition to Telehealth. Nicotine Tob Res. 2022 Mar.24(5):794-798. Pubmedid: 34929731. Pmcid: PMC8962722.
- Shoenbill KA, Baca-Atlas MH, Smith CA, Wilhoit-Reeves SB, Baca-Atlas SN, Goldstein AO. Evaluating a Tobacco Treatment Program's Transition to Telehealth Using a Social Determinants of Health Lens. Nicotine Tob Res. 2022 Apr.24(6):904-908. Pubmedid: 35038749. Pmcid: PMC9272290.
- Jonas DE, Barclay C, Grammer D, Weathington C, Birken SA, DeWalt DA, Shoenbill KA, Boynton MH, Mackey M, Riley S, Cykert S. The STUN (STop UNhealthy) Alcohol Use Now trial: study protocol for an adaptive randomized trial on dissemination and implementation of screening and management of unhealthy alcohol use in primary care. Trials. 2021 Nov.22(1):810. Pubmedid: 34784953. Pmcid: PMC8593635.
- Crane TE, Tsoh JY, Hohl SD, Goldstein AO, Lenhoff KL, Ostroff J, Shoenbill K, Fugate-Laus K, Park ER, Peregoy J, Warren GW, Adsit R, Minion M, Pauk D, Rolland B. Involving Family and Social Support Systems in Tobacco Cessation Treatment for Patients With Cancer. J Natl Compr Canc Ne. 2021 Nov.19(Suppl_1):S8-S11. Pubmedid: 34872052. Pmcid: PMC9062988.
- Salloum RG, Fleisher L, Hohl SD, Clark SV, Klass E, Dahl NA, Pike B, Lenhoff KL, Presant CA, Shoenbill KA, Ramsey AT, Jose T, Day AT, Dark M, Yeung S, Tong EK, Prochaska JJ, Ostroff JS, Shelley D, Warren GW, Adsit R, Minion M, Pauk D, Rolland B. Sustainability of Tobacco Treatment Programs in the Cancer Center Cessation Initiative. J Natl Compr Canc Ne. 2021 Nov.19(Suppl_1):S16-S20. Pubmedid: 34872053. Pmcid: PMC9036976.
- Rigotti NA, Taylor KL, Beneventi D, King A, Kotsen C, Fleisher L, Goldstein AO, Park ER, Sherman SE, Steinberg MB, Albert DA, Cox LS, Hayes RB, Hohl SD, Sheffer CE, Shoenbill KA, Simmons VN, Warren GW, Adsit R, Minion M, Pauk D, Rolland B. Telehealth Delivery of Tobacco Cessation Treatment in Cancer Care: An Ongoing Innovation Accelerated by the COVID-19 Pandemic. J Natl Compr Canc Ne. 2021 Nov.19(Suppl_1):S21-S24. Pubmedid: 34872049. Pmcid: PMC9040141.
- Zerden LS, Lombardi BM, Richman EL, Fraher EP, Shoenbill KA. Harnessing the electronic health record to advance integrated care. Fam Syst Health. 2021 Mar.39(1):77-88. Pubmedid: 34014732.
- Goldstein AO, Shoenbill KA, Jolly TA. Intensive Smoking Cessation Counseling for Patients With Cancer. Jama. 2020 Oct.324(14):1401-1403. Pubmedid: 33048141.
- Shoenbill K, Song Y, Gress L, Johnson H, Smith M, Mendonca EA. Natural language processing of lifestyle modification documentation. Health Informatics J. 2020 Mar.26(1):388-405. Pubmedid: 30791802. Pmcid: PMC6722039.
- Shoenbill K, Song Y, Craven M, Johnson H, Smith M, Mendonca EA. Identifying patterns and predictors of lifestyle modification in electronic health record documentation using statistical and machine learning methods. Prev Med. 2020 Jul.136:106061. Pubmedid: 32179026. Pmcid: PMC7314106.
- Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Am Med Inform Assoc. 2019 Apr.26(4):276-285. Pubmedid: 30840079. Pmcid: PMC6402312.
- Shoenbill K, Song Y, Cobb NL, Drezner MK, Mendonca EA. IRB Process Improvements: A Machine Learning Analysis. J Clin Transl Sci. 2017 Jun.1(3):176-183. Pubmedid: 29082031. Pmcid: PMC5647673.
- Shoenbill K, Fost N, Tachinardi U, Mendonca EA. Genetic data and electronic health records: a discussion of ethical, logistical and technological considerations. J Am Med Inform Assoc. 2014 Feb.21(1):171-180. Pubmedid: 23771953. Pmcid: PMC3912723.
-
Patient Comments
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments